Alcántar-Luna E, Carrillo-Esper R, Herrera-Cornejo MA, Jaimovich D, López-García L, Ramos-Corrales MA, Valero RJE, Vázquez DIM, Villagómez OA, Aldrete VJ, Luna LDA, Cote EL, Pérez-Castro JA

Language: Spanish
References: 28
Page: 356-369
PDF size: 611.72 Kb.

ABSTRACT

Venous thromboembolic disease is a major cause of morbidity and hospital mortality in the world. Although exact figures are unknown in our country, to achieve uniformity of criteria among the specialties involved in the prophylaxis and treatment will have a clearer picture of this entity and contribute to a more rational and interdisciplinary approach, managing to improve the quality of care for patients and raise the level of awareness of this entity. This is a sufficient justification for the effort led by collegiate work of experts and specialists in the field, was given the task of developing a management algorithm for prophylaxis in hospitalized patients at risk of venous thromboembolic disease. This group of experts at a plenary working session, achived uniformity criteria and reached agreement by consensus, so that the bibliography is updated and revised to try to adapt to our current hospital situation.

REFERENCES

1. Sigler ML, Castañeda GR, Athié RJ. Trombosis venosa profunda y embolia pulmonar. México: McGraw-Hill Interamericana, 2002.

2. Villagómez A. Guías para el diagnóstico, prevención y tratamiento de la enfermedad tromboembólica venosa. Grupo de trabajo. Rev Mex Anestesiol 2006;29 (Supl 2 oct-dic); S303-S334.

3. Grendys E, Fiorica J. Advances in the prevention and treatment of deep vein thrombosis and pulmonary embolism. Curr Op Obstet Gynecol 1999;11:71-79.

4. Hettiarachi RJ, Lok J, Prins MH, et al. Undiagnosed malignancy in patients with deep vein thrombosis: incidence, risk, indicators and diagnosis. Cancer 1998;83:180-85.

5. Villagómez A, Hernández S, Castro M, y col. Tromboembolia pulmonar. Acta Med Gpo Ang 2005;3(1):33-39.

6. Bottaro FJ, Elizondo MC, Doti C, et al. Efficacy of extended thrombo-prophylaxis in major abdominal surgery: What does the evidence show? A meta-analysis. Thromb Haemost 2008;99(6):1104-1111.

7. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Antithrombotic and thrombolytic therapy. Prevention of Venous Thromboembolism. CHEST 2008, 8th ed. 381S-453S.

8. Carrillo R, Zaragoza G, Mejía G, y col. Guía de práctica clínica basada en la evidencia para el manejo de anestesia regional y anticoagulación. Revista Mexicana de Anestesiología 2009;32 (2) S247-S276.

9. Majluf A, Villagómez A, y col. Recomendaciones para el diagnóstico, prevención y tratamiento de la enfermedad tromboembólica venosa. Gaceta Médica de México 2007; 143(S1): 1-49.

10. Ochoa FJ, Carrillo R, Escudero PM, y col. Parámetros de práctica clínica basados en evidencia en tromboprofilaxis: diagnóstico y tratamiento de la enfermedad tromboembólica en el paciente con cáncer. GAMO 2009;8 (S4): 7-27.

11. Allen DJ, Chae-Kim SH, Trousdale DM. Risks and complications of neuraxial anesthesia and the use of anticoagulation in the surgical patient. Proc (Bayl Univ Med Cent) 2002;15:369-373.

12. Horlocker TT, Wedel DJ, Benzon H, et al. Regional anesthesia in the anticoagulated patient: defining the risks (the second ASRA Consensus Conference on Neuraxial Anesthesia and Anticoagulation). Reg Anesth Pain Med 2003;28:172-197.

13. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924-926.

14. Sandoval ZJ, Martínez GM, Gómez A, y col. Tromboembolia pulmonar aguda. PAC Cardio-1. Sociedad Mexicana de Cardiología. México: Intersistemas, 1998;7-9.

15. Martínez C. Diagnóstico de la enfermedad tromboembólica venosa. México: Guía práctica. Alfil,2007 (9): 123-129.

16. Hoffman M, Monroe DM. Coagulation 2006: A modern view of hemostasis. Hematol Oncol Clin N Am 2007;21:1-11.

17. Brinkhous KM. Smth HP, et al. The inhibition of blood clotting: an unidentified substance, which acts in conjunction with heparin to prevent the conversion of prothrombin into thrombin. Am J Physiol 1999;125:683-687.

18. Pineda L, Hathwar VS, Grant BJ. Clinical suspicion of fatal pulmonary embolism. Chest 2001;120:791-795.

19. Dalen JE. Pulmonary embolism: what have we learned since Virchow? Natural history, pathophisiology and diagnosis. Chest 2002;122:1440-1456.

20. Douketis JD, Kearon C, Bates S, et al. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA 1998;279:458-462.

21. Suárez C. Tratamiento ambulatorio de la enfermedad tromboembólica venosa. Med Clin (Barc) 2002; 3 (Supl. 2): 43-45.

22. Hanson PO, Welin L, Tibblin G, et al. Deep vein thrombosis and pulmonary embolism in the general population. Arch Intern Med 1997;157:1665-1670.

23. Silverstein MD, Heit JA, Mohr DN, et al. Trends in the incidence of deep vein thromboses and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998;158:585-593.

24. Heit J, Melton LJ, Lohse CM, Petterson, et al. Incidence of venous thromboembolism in hospitalized patients vs community residents. Mayo Clin Proc 2001;76:1102-1110.

25. ACC/AHA. Guidelines for the Management of Patients with ST-elevation Myocardial Infarction. Circulation 2004;110:588-636.

26. ACC/AHA. Guidelines for the Management of Patients without ST-elevation Coronary Syndrome. Circulation 2000;102:1193.

27. Reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital. This guideline updates NICE clinical guideline. January 2010

28. Venous tromboembolism: reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital. National Clinical Guideline Centre, 2009.